Homology Medicines, Inc. (0T6G.L)
USD 2.07
(12.17%)
USD 2.07
(12.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -47.75 Million USD | 63.46% |
| 2022 | 3.79 Million USD | -51.24% |
| 2021 | -86.22 Million USD | 28.8% |
| 2020 | -119.79 Million USD | -17.11% |
| 2019 | -103.62 Million USD | -76.72% |
| 2018 | -58.63 Million USD | -102.38% |
| 2017 | -29.3 Million USD | -196.85% |
| 2016 | -7.8 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -14.72 Million USD | 42.69% |
| 2024 Q2 | -17.79 Million USD | -20.91% |
| 2023 Q3 | -24.22 Million USD | 19.92% |
| 2023 Q4 | -9.41 Million USD | 61.14% |
| 2023 Q1 | -26.92 Million USD | 20.49% |
| 2023 FY | - USD | 29.96% |
| 2023 Q2 | -30.25 Million USD | -12.36% |
| 2022 Q1 | -37.07 Million USD | -18.71% |
| 2022 Q4 | -33.86 Million USD | -5.07% |
| 2022 Q2 | -27.52 Million USD | 25.77% |
| 2022 Q3 | -32.22 Million USD | -17.1% |
| 2022 FY | - USD | -51.24% |
| 2021 Q2 | -28.16 Million USD | -2356.49% |
| 2021 FY | - USD | 28.8% |
| 2021 Q1 | 1.24 Million USD | 104.5% |
| 2021 Q4 | -31.23 Million USD | -10.5% |
| 2021 Q3 | -28.26 Million USD | -0.36% |
| 2020 Q4 | -27.74 Million USD | -5.65% |
| 2020 FY | - USD | -17.11% |
| 2020 Q2 | -33.7 Million USD | 2.54% |
| 2020 Q1 | -34.58 Million USD | -45.07% |
| 2020 Q3 | -26.26 Million USD | 22.08% |
| 2019 Q3 | -29.59 Million USD | -12.4% |
| 2019 Q1 | -23.85 Million USD | -21.66% |
| 2019 FY | - USD | -76.72% |
| 2019 Q4 | -23.84 Million USD | 19.45% |
| 2019 Q2 | -26.33 Million USD | -10.37% |
| 2018 Q2 | -13.18 Million USD | -25.87% |
| 2018 Q4 | -19.6 Million USD | -27.6% |
| 2018 FY | - USD | -102.38% |
| 2018 Q1 | -10.47 Million USD | 13.15% |
| 2018 Q3 | -15.36 Million USD | -16.55% |
| 2017 Q1 | -4.56 Million USD | 0.0% |
| 2017 FY | - USD | -196.85% |
| 2017 Q3 | -6.47 Million USD | -10.21% |
| 2017 Q4 | -12.06 Million USD | -86.28% |
| 2017 Q2 | -5.87 Million USD | -28.8% |
| 2016 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.442% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 86.176% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 82.046% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 59.408% |
| uniQure N.V. | -253.1 Million USD | 81.132% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 48.136% |
| bluebird bio, Inc. | -167.16 Million USD | 71.431% |
| Imunon, Inc. | -20.78 Million USD | -129.792% |
| Dynavax Technologies Corporation | 9.66 Million USD | 594.062% |
| Editas Medicine, Inc. | -163.11 Million USD | 70.723% |
| Illumina, Inc. | -608 Million USD | 92.145% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 89.364% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 101.467% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 104.103% |
| Myriad Genetics, Inc. | -67.8 Million USD | 29.563% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 111.477% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 89.126% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 148.601% |
| Verastem, Inc. | -83.16 Million USD | 42.577% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.577% |
| Waters Corporation | 1.02 Billion USD | 104.672% |
| Biogen Inc. | 2.37 Billion USD | 102.009% |
| Nektar Therapeutics | -243.1 Million USD | 80.356% |
| Perrigo Company plc | 646.2 Million USD | 107.39% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -7.47% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 53.989% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -28.091% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 115.391% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 45.376% |
| Evolus, Inc. | -41.81 Million USD | -14.221% |
| Adicet Bio, Inc. | -136.53 Million USD | 65.023% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 45.723% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.026% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 68.186% |
| FibroGen, Inc. | -261.4 Million USD | 81.731% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 102.848% |
| OPKO Health, Inc. | -65.51 Million USD | 27.108% |
| Geron Corporation | -174.78 Million USD | 72.677% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 79.065% |
| Exelixis, Inc. | 196.6 Million USD | 124.291% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 52.636% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 14.348% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 90.568% |
| Zoetis Inc. | 3.68 Billion USD | 101.296% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 78.774% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 5.568% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.037% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -32.354% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 79.237% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 144.086% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 110.567% |
| Blueprint Medicines Corporation | -474.61 Million USD | 89.938% |
| Insmed Incorporated | -654.73 Million USD | 92.706% |
| TG Therapeutics, Inc. | 26.1 Million USD | 282.973% |
| Incyte Corporation | 919.42 Million USD | 105.194% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 90.549% |